// App-Quantinova.ai

Filters

Biomarkers











Conference Name











Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























914 Abstracts

Specific Antibodies in Interstitial Lung Disease

J. Graham - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Idiopathic pulmonary fibrosis

N/A

Diagnostic Role of Measurement of Asbestos Bodies in Bronchoalveolar Lavage Fluid in Patients with Interstitial Lung Diseases

Y. Inagaki - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Center Prospective Cohort Study of Diagnostic Procedure of Interstitial Pneumonia in Clinical Setting; The Importance of Distinguishing Chronic Hypersensitivity Pneumonitis from Idiopathic Pulmonary Fibrosis

M. Ishizuka - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic pulmonary fibrosis

N/A

Atypical Explant Histopathology in Idiopathic Pulmonary Fibrosis and Severe Pulmonary Hypertension

L. Sullivan - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Idiopathic pulmonary fibrosis

N/A

a Real Life Multicentric Experience

D. Lacedonia - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Idiopathic pulmonary fibrosis

Pirfenidone

Interstitial Lung Disease Characteristics at the Veterans Affairs Long Beach Healthcare System

K. M. Stern - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Induced Silicosis; Correlation to Occupational, Clinical and Functional Parameters

E. M. Fireman - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Smoking Prevalence and Characterization of Patients at Diagnosis of Diffuse Interstitial Lung Diseases

N. Albacar Ingla - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic pulmonary fibrosis

N/A

A Nationwide Study of Patients Characteristics for Idiopathic Pulmonary Fibrosis in 2014

J. Tran - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Deployment to Iraq and Afghanistan but Is Not Seen in Lungs of Five Patients with Idiopathic Pulmonary Fibrosis

P. Huang - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Fibrinolytic System and Epithelial to Mesenchymal Transition During Lung Injury and Fibrosis In Vitro and In Vivo

S. Shaikh - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Interleukin

In Vitro Studies on the Impact of Ergothioneine on Idiopathic Pulmonary Fibrosis Markers in Human Lung Epithelial Cells

C. Koay - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

sodium pyruvate

T Cell Phenotype in Peripheral Blood of Patients with Idiopathic Pulmonary Fibrosis

A. Serezani - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Term Longitudinal Gene Expression Changes Predict Forced Vital Capacity Decline in Idiopathic Pulmonary Fibrosis

Y. Huang - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Analysis of Randomized Controlled Trials

Y. Zayed - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Nontuberculous Mycobacterial Pulmonary Disease in Patients with Interstitial Pneumonia

Y. Goto - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Quantitative Proteomic Profiling of Extracellular Matrix and Collagen Posttranslational Modifications in an In Vitro Model of Lung Fibrosis

C. A. Staab-Weijnitz - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Resolution Computed Tomography Measures of Lung Parenchyma and Airway Morphometry in Patients with Interstitial Lung Disease

K. Ikezoe - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Development and Testing of a Formula for Predicting Emphysema Extent in Patients with Idiopathic Pulmonary Fibrosis

A. U. Wells - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

877, a Potent Autotaxin Inhibitor in Clinical Development to Treat Idiopathic Pulmonary Fibrosis

G. Lee - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Bleomycin

Copyright © 2026. QuantiNova All rights reserved